SAN DIEGO, July 31, 2023 (GLOBE NEWSWIRE) -- Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB:SIGY), a development-stage company that creates therapeutic blood purification candidates to overcome clearly defined limitations in healthcare, today announced that Jim Joyce, Chairman and CEO, will present live at the OTCQB Venture Virtual Investor Conference on August 3rd, 2023.
DATE: Thursday, August 3rd
TIME: 1:30 to 2PM Eastern
LINK: https://bit.ly/3OuMTGu
1x1 meeting opportunities with management: August 4th, 5th, and 7th from 12pm to 5pm Eastern.
This is a live, interactive online event. Investors are invited to ask management questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will be made available after the event.
It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.
Learn more at www.virtualinvestorconferences.com
Recent Company Highlights
- The Company disclosed plans to enroll end-stage renal disease (ESRD) with endotoxemia as the first indication to be enrolled in human studies of Sigyn TherapyTM, a medical technology designed to treat pathogen-associated inflammatory disorders that are not addressed with market-cleared drug agents.
- The Company introduced ChemoPrepTM and ChemoPureTM, which comprise a system designed to improve chemotherapy delivery and reduce its toxicity. Current limitation of chemotherapy: Poor delivery and toxicity. Less than 3.5% of infused chemotherapy reaches its target tumor site.
- The Company introduced ImmunePrepTM, a novel commercialization platform designed to enhance the delivery of therapeutic antibodies, including cancer checkpoint inhibitors. Current limitation of therapeutic antibodies: Less than 5% of infused antibodies are delivered to their therapeutic target.
About Sigyn Therapeutics™
Sigyn Therapeutics creates therapeutic blood purification candidates to overcome clearly defined limitations in healthcare. The Company’s leadership team has extensive public market and medical technology experience, which includes multiple first-in-industry achievements.
Sigyn Therapy™ is being advanced to treat pathogen-associated inflammatory disorders that are not addressed with market-cleared drug agents. Candidate treatment indications include endotoxemia, sepsis (leading cause of hospital deaths), community acquired pneumonia (a leading cause of death among infectious diseases), and emerging drug-resistant bacterial and pandemic viral threats.
The Company recently disclosed plans to initiate human studies of Sigyn TherapyTM in end-stage renal disease (ESRD) patients diagnosed with endotoxemia, a condition associated with multi-organ dysfunction and severe sepsis. In the United States, it is estimated that upwards of 50% of 550,000+ ESRD patients suffer from endotoxemia each year.
Beyond the advancement of Sigyn Therapy, the Company believes its therapeutic pipeline is among the most expansive and compelling in the extracorporeal blood purification industry.
ChemoPrep™ and ChemoPure™ comprise a system designed to improve the tumor-site saturation of chemotherapy yet reduce treatment toxicity. ImmunePrepTM is a novel commercialization platform designed to enhance the efficacy of therapeutic antibodies (including cancer checkpoint inhibitors), whose 2022 global market of $186.6 billion (USD) is projected to reach $566.72 billion (USD) in 2032.
To learn more about Sigyn Therapeutics, visit: www.SigynTherapeutics.com.
About Virtual Investor Conferences®
Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.
Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.
Cautionary Note Regarding Forward-Looking Statements
This information in this press release contains forward-looking statements of Sigyn Therapeutics, Inc. (“Sigyn”) that involve substantial risks and uncertainties. All statements contained in this summary are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Sigyn's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences may include, without limitation, the Company's ability to clinically advance Sigyn Therapy in human studies required for market clearance, the Company's ability to manufacture Sigyn Therapy, the Company's ability to raise capital resources, and other potential risks. The foregoing list of risks and uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2022, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this report speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.
CONTACTS:
Sigyn Therapeutics, Inc.
Charlene Owen
Director of Operations
858-353-0800 x100
Charlene@SigynTherapeutics.com
Virtual Investor Conferences
John M. Viglotti
SVP Corporate Services, Investor Access
OTC Markets Group
(212) 220-2221
johnv@otcmarkets.com
